<DOC>
	<DOCNO>NCT00560833</DOCNO>
	<brief_summary>The direct treatment vasomotor symptions ( hot flush ) may mean 5-HT2A receptor antagonist . Mirtazapine potent blocker 5-HT2A receptor find effective reduce number intensity hot flush preliminary trial . Also several Selective Serotonin Reuptake Inhibitors ( SSRIs ) similar compound investigated manage hot flush , confirm role serotonergic system . In present trial , efficacy safety four different dos esmirtazapine compare placebo investigate woman moderate severe vasomotor symptom associate menopause . The primary study hypothesis esmirtazapine would show superior efficacy placebo .</brief_summary>
	<brief_title>Dose-Finding Safety Efficacy Trial Org50081 ( Esmirtazapine ) Treatment Vasomotor Symptoms ( 46101/P06459/MK-8265-012 )</brief_title>
	<detailed_description />
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>postmenopausal woman , define : 12 month spontaneous amenorrhea ; OR 6 month spontaneous amenorrhea serum Follicle Stimulating Hormone ( FSH ) level &gt; 40 mIU/mL ; OR 6 week post surgical bilateral oophorectomy without hysterectomy . In case menopausal status subject unclear hysterectomy , serum FSH level &gt; 40 mIU/mL . If date last menstruation clear perimenopausal hormone use , subject serum FSH level &gt; 40 mIU/mL completion washout period ( see exclusion criterion ) ; &gt; = 40 &lt; = 65 year age ; body mass index ( BMI ) &gt; = 18 &lt; = 32 kg/m^2 ; minimum 7 moderate severe hot flush per day 50 per week , quantify daily diary recording least 7 day precede randomization trial medication ; able handle electronic diary device training least 80 % compliance complete daily diary entry period prior randomization ; give voluntary write Informed Consent ( IC ) scope nature investigation explain , screen evaluation . history presence malignancy , except nonmelanoma skin cancer clinically unstable uncontrolled renal , hepatic , endocrine , respiratory , hematological , neurological , cardiovascular , cerebrovascular disease would put subject safety risk mask measure efficacy history seizures epilepsy ; history presence clinically significant depression psychiatric disorder , opinion investigator , might compromise confound participant 's participation trial ; abnormal clinically relevant vaginal bleeding clinically relevant ( opinion investigator ) abnormal find physical , gynecological breast examination screening ; abnormal , clinically significant result mammography . Mammography perform within last 9 month prior screen , otherwise do inclusion trial . For nonUS site , local law guideline allow advise frequent mammogram , document local law guideline follow ; abnormal cervical smear test result ( correspond Pap III high , include LowGrade Squamous Intraepithelial Lesion ( LSIL ) , HighGrade Squamous Intraepithelial Lesion ( HSIL ) , Cervical Intraepithelial Neoplasia ( CIN ) 1 high ) . A cervical smear perform within last 9 month prior screen , otherwise do inclusion trial ; hematological biochemical value screen outside reference range consider clinically relevant opinion investigator high blood pressure ( BP ) ( sit systolic BP &gt; 170 mmHg and/or diastolic BP &gt; 100 mmHg ) use drug product contain estrogen , progestin , androgen , tibolone prior screen ( include randomization ) within specify time frame</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>